Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeoVax Labs, Inc. filings document a clinical-stage biotechnology issuer developing multi-antigenic vaccines and immunotherapies for infectious diseases and cancer. The company’s regulatory disclosures cover operating and financial results, research and development activity, clinical and regulatory updates for programs such as GEO-MVA, GEO-CM04S1 and Gedeptin, and risks associated with development-stage biotechnology operations.
Its SEC record also includes proxy materials on governance, executive compensation and equity awards; registration statements and 8-K reports covering common stock, warrants, registered offerings and other capital-structure matters; and material-event disclosures related to agreements, reporting status and shareholder voting matters.
GeoVax Labs, Inc. may currently offer and sell shares of its common stock with an aggregate offering price of up to approximately $5,925,259 under its existing at‑the‑market stock offering program with A.G.P./Alliance Global Partners. This prospectus supplement updates earlier prospectuses after the company became subject to Form S‑3 General Instruction I.B.6, which limits primary offerings to no more than one‑third of the public float in any twelve‑month period while the float remains below $75 million.
Under the original prospectus, GeoVax registered up to $30,000,000 of common stock for sale through the ATM and has already sold 3,964,770 shares for gross proceeds of $8,950,918. The aggregate market value of common stock held by non‑affiliates is about $21,548,168, based on 25,320,996 non‑affiliate shares at $0.851 per share as of July 23, 2025, and the company has sold approximately $1,257,464 of securities under I.B.6 in the past twelve months.